GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Cyclically Adjusted PB Ratio

GTBP (GT Biopharma) Cyclically Adjusted PB Ratio : (As of Sep. 24, 2024)


View and export this data going back to . Start your Free Trial

What is GT Biopharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GT Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for GT Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma Cyclically Adjusted PB Ratio Chart

GT Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GT Biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GT Biopharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, GT Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Cyclically Adjusted PB Ratio falls into.



GT Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

GT Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, GT Biopharma's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=2.465/132.5538*132.5538
=2.465

Current CPI (Jun. 2024) = 132.5538.

GT Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201409 -316.382 100.428 -417.590
201412 -864.941 99.070 -1,157.278
201503 -1,463.735 99.621 -1,947.616
201506 -668.647 100.684 -880.297
201509 -717.147 100.392 -946.898
201512 -1,482.441 99.792 -1,969.120
201603 -143,235.714 100.470 -188,975.441
201606 -92,152.941 101.688 -120,124.405
201609 -94,666.667 101.861 -123,191.668
201612 -93,790.000 101.863 -122,048.806
201703 -22,430.000 102.862 -28,904.512
201706 -20,534.021 103.349 -26,336.587
201709 2,601.814 104.136 3,311.839
201712 2,562.898 104.011 3,266.208
201803 2,568.678 105.290 3,233.827
201806 2,505.638 106.317 3,123.983
201809 136.867 106.507 170.339
201812 116.160 105.998 145.262
201903 101.092 107.251 124.942
201906 88.560 108.070 108.624
201909 -138.152 108.329 -169.045
201912 -139.911 108.420 -171.054
202003 -149.455 108.902 -181.915
202006 -184.944 108.767 -225.390
202009 -194.954 109.815 -235.322
202012 -169.231 109.897 -204.121
202103 35.363 111.754 41.945
202106 38.863 114.631 44.939
202109 31.510 115.734 36.089
202112 20.500 117.630 23.101
202203 16.498 121.301 18.028
202206 15.090 125.017 16.000
202209 14.722 125.227 15.583
202212 10.757 125.222 11.387
202303 10.616 127.348 11.050
202306 8.683 128.729 8.941
202309 7.246 129.860 7.396
202312 5.414 129.419 5.545
202403 3.847 131.776 3.870
202406 2.465 132.554 2.465

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GT Biopharma  (NAS:GTBP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


GT Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GT Biopharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Executives
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen director, officer: Exec. Chair. and Interim CEO LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri officer: CFO & Secretary 2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel director 70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk officer: Pres. of R&D, CMO HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban director 1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy officer: Acting Chief Financial Officer 8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon director, officer: CFO 7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross director, officer: Chief Executive Officer 1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski officer: Chief Medical Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith director, 10 percent owner, officer: CEO 1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman 10 percent owner 224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc 10 percent owner
Bristol Investment Fund Ltd 10 percent owner 89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205

GT Biopharma Headlines

From GuruFocus

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

By Stock market mentor Stock market mentor 02-02-2023